Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Farkasgyepu – page 2

22 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Farkasgyepu at a glance
22
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

22 trials in Farkasgyepu

Open in trial search
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Kappa Monoclonal Antibody Against Crlf2
  • Sponsor:Upstream Bio Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amg 193
  • Sponsor:Amgen Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC
Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Hungary

The busiest research cities in the country

All 70 cities in Hungary

Clinical research in Farkasgyepu

What the registry says about research in the country

01 Lung Cancer Immunotherapy

Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.

  • Novel immunotherapy combinations
  • PD-L1 targeted therapies
  • First-line treatment strategies

Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.

02 Advanced NSCLC Treatments

Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.

  • Mutation-specific treatments
  • Combination therapy approaches
  • Novel drug development

Investigations focus on personalized treatment strategies for different NSCLC subtypes.

03 Small Cell Lung Cancer Research

Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.

  • Single-agent therapies
  • Combination treatments
  • Survival outcome studies

Research focuses on improving treatment options for patients with relapsed SCLC.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.